Michael Overholtzer

Michael Overholtzer

Auto-generated profile, based on publicly available information

Michael Overholtzer

Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; BCMB Graduate Program, Weill Cornell Medical College, New York, NY 10065, USA; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Cell
Verified
Journal Article
Closed access
MOMichael Overholtzer
Michael Overholtzer
AMArnaud A. Mailleux
Arnaud A. Mailleux
GMGhassan Mouneimne
Ghassan Mouneimne
GNGuillaume Normand
Guillaume Normand
SSStuart J. Schnitt
Stuart J. Schnitt
JBJoan S. Brugge
Joan S. Brugge

26 September 2016 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
SKSung Eun Kim
Sung Eun Kim
LZLi Zhang
Li Zhang
KMKai Ma
Kai Ma
MRMichelle Riegman
Michelle Riegman
FCFeng Chen
Feng Chen
MOMichael Overholtzer
Michael Overholtzer
The design of cancer-targeting particles with precisely tuned physicochemical properties may enhance the delivery of therapeutics and access to pharmacological targets. However, a molecular-level understanding of the interactions driving the fate of nanomedicine in biological systems remains elusive. Here, we show that ultrasmall (<10 nm in diameter) poly(ethylene glycol)-coated silica nanoparticles, functionalized with melanoma-targeting peptides, can induce a form of programmed cell death known as ferroptosis in starved cancer cells and cancer-bearing mice. Tumour xenografts in mice intravenously injected with nanoparticles using a high-dose multiple injection scheme exhibit reduced growth or regression, in a manner that is reversed by the pharmacological inhibitor of ferroptosis, liproxstatin-1. These data demonstrate that ferroptosis can be targeted by ultrasmall silica nanoparticles and may have therapeutic potential.

16 October 2011 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
OFOliver Florey
Oliver Florey
SKSung Eun Kim
Sung Eun Kim
CSCynthia P. Sandoval
Cynthia P. Sandoval
CHCole M. Haynes
Cole M. Haynes
MOMichael Overholtzer
Michael Overholtzer

31 August 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MRMichelle Riegman
Michelle Riegman
LSLiran Sagie
Liran Sagie
CGChen Galed
Chen Galed
TLTom Levin
Tom Levin
NSNoah Steinberg
Noah Steinberg
MOMichael Overholtzer
Michael Overholtzer

24 October 2014 in Cell Research
Verified
Journal Article
Closed access
QSQiang Sun
Qiang Sun
TLTianzhi Luo
Tianzhi Luo
YRYixin Ren
Yixin Ren
OFOliver Florey
Oliver Florey
SSSenji Shirasawa
Senji Shirasawa
MOMichael Overholtzer
Michael Overholtzer

14 November 2014 in Autophagy
Verified
Journal Article
Open access
OFOliver Florey
Oliver Florey
NGNoor Gammoh
Noor Gammoh
SKSung Eun Kim
Sung Eun Kim
XJXuejun Jiang
Xuejun Jiang
MOMichael Overholtzer
Michael Overholtzer
Recently a noncanonical activity of autophagy proteins has been discovered that targets lipidation of microtubule-associated protein 1 light chain 3 (LC3) onto macroendocytic vacuoles, including macropinosomes, phagosomes, and entotic vacuoles. While this pathway is distinct from canonical autophagy, the mechanism of how these nonautophagic membranes are targeted for LC3 lipidation remains unclear. Here we present evidence that this pathway requires activity of the vacuolar-type H+-ATPase (V-ATPase) and is induced by osmotic imbalances within endolysosomal compartments. LC3 lipidation by this mechanism is induced by treatment of cells with the lysosomotropic agent chloroquine, and through exposure to the Heliobacter pylori pore-forming toxin VacA. These data add novel mechanistic insights into the regulation of noncanonical LC3 lipidation and its associated processes, including LC3-associated phagocytosis (LAP), and demonstrate that the widely and therapeutically used drug chloroquine, which is convention...